190P - Real-world applications of poly (ADP-ribose) polymerase inhibitors for ovarian cancer: A single-center study in China

Background

Olaparib and niraparib have been approved for first/second-line maintenance treatment of ovarian cancer patients in China for more than 3 years. In this study, we analyzed the clinical application characteristics of PARPi in the maintenance therapy of ovarian cancer in real world to promote their rational application.

Methods

Retrospective chart review identified patients prescribed Ola, Nira for maintenance therapy of newly diagnosed or recurrent ovarian cancer from Sichuan cancer hospital in China between 1 July 2018 and 30 November 2021. Their medical records including pathologic, treatment and genetic information were reviewed.

Results

131 patients were finally enrolled（67 Ola 51%; 64 Nira, 49%), data collection time was up to 7 May, 2022. 63% (42/67) of patients were detected to have BRCA mutations in the Ola group especially higher in the 1st line maintenance setting (92% 32/35). More than 90%(58/64) of patients were BRCA wild type or unknow in the Nira group. The median follow-up time was 16.9 months in the Ola group, and 16.3 months in Nira group. The median duration of treatment (DOT) of was 14.3 months in the Ola group, and 13.5 months in the Nira group. At the time of data censoring, 87 (66.4%) patients were still on treatment. The PFS rate at 24-month（PFS 24）was 56.2%(95CI:0.40-0.78) in the Ola group, and 58.8%(95CI:0.47-0.74) in the Nira group. The PFS 24 of 1 Lm was 60.4%(95CI:0.37-0.88) in the Ola group, and 66.3%(95CI:0.54-0.82) in the Nira group. PFS rate at 12-month (PFS 12) of recurrence patients was 80% (95%CI:0.68-0.95) in the Ola group, and 50% (95%CI:0.30-0.82) in the Nira group. No new safety signal was observed. Dose discontinuations were observed in 1 patient with Nira due to ALL,2 patients with Ola due to thrombocytopenia and AML. We also observed that patients with skin pigmentation had a reduced probability of AEs. Table: 190P

Conclusions

The efficacy of PARP inhibitors in maintenance therapy was consistent to previously reported randomized clinical trials (NOVA, SOLO-2, SOLO-1 and PRIMA), Both Olaparib and Niraparib significantly improved the progression free survival of ovarian cancer without new safety signals.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.